Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2

[1]  B. Weynand,et al.  Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity , 2020, Proceedings of the National Academy of Sciences.

[2]  S. Kent,et al.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies , 2020, Nature Microbiology.

[3]  K. To,et al.  COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  K. To,et al.  A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2 , 2020, Nature Communications.

[5]  A. Osman,et al.  Re-positive coronavirus disease 2019 PCR test: could it be a reinfection? , 2020, New Microbes and New Infections.

[6]  Z. Zhong,et al.  Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies , 2020, Frontiers in Immunology.

[7]  Eytan Ruppin,et al.  Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning , 2020, Nature.

[8]  M. Müller,et al.  Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 , 2020, Nature.

[9]  X. de Lamballerie,et al.  Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates , 2020, Nature.

[10]  Otto O. Yang,et al.  Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19 , 2020, The New England journal of medicine.

[11]  S. Perlman,et al.  Lessons for COVID-19 Immunity from Other Coronavirus Infections , 2020, Immunity.

[12]  R. Spreafico,et al.  A perspective on potential antibody-dependent enhancement of SARS-CoV-2 , 2020, Nature.

[13]  Mengji Lu,et al.  Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery , 2020, Clinical Microbiology and Infection.

[14]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[15]  W. Xu,et al.  The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin , 2020, Signal Transduction and Targeted Therapy.

[16]  L. Parida,et al.  Variant analysis of SARS-CoV-2 genomes , 2020, Bulletin of the World Health Organization.

[17]  Z. Memish,et al.  Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review , 2020, Travel Medicine and Infectious Disease.

[18]  Wu Zhong,et al.  The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro , 2020, Cell Discovery.

[19]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[20]  J. Huang,et al.  Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study , 2020, Clinical Microbiology and Infection.

[21]  André Machado Siqueira,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[22]  Mathieu E. Rebeaud,et al.  SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment , 2020, Frontiers in Medicine.

[23]  Fabian J Theis,et al.  SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.

[24]  O. Tsang,et al.  Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.

[25]  Zhen Zhu,et al.  Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 , 2020, Journal of Infection.

[26]  Zhènglì Shí,et al.  Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion , 2020, Cell Research.

[27]  K. To,et al.  Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Fabian J Theis,et al.  SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways , 2020, Nature Medicine.

[29]  Fumihiro Kato,et al.  Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.

[30]  Jianjun Gao,et al.  Discovering drugs to treat coronavirus disease 2019 (COVID-19). , 2020, Drug discoveries & therapeutics.

[31]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[32]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[33]  E. Boyer,et al.  Chloroquine, hydroxychloroquine and COVID-19 , 2020, Toxicology communications.

[34]  S. Polyak,et al.  Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses , 2019, Journal of Virology.

[35]  K. To,et al.  Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza , 2018, Nature Communications.

[36]  Florian Krammer,et al.  An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin‐Bearing Influenza Viruses , 2017, Immunity.

[37]  I. Wilson,et al.  Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol , 2016, Proceedings of the National Academy of Sciences.

[38]  K. Yuen,et al.  Novel residues in the PA protein of avian influenza H7N7 virus affect virulence in mammalian hosts. , 2016, Virology.

[39]  Fang Li,et al.  Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.

[40]  Chao Lu,et al.  Retrospective study , 2016, Medicine.

[41]  Ke Zhang,et al.  A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses , 2016, Scientific Reports.

[42]  H. Feldmann,et al.  Lack of Protection Against Ebola Virus from Chloroquine in Mice and Hamsters , 2015, Emerging infectious diseases.

[43]  Yanchen Zhou,et al.  Protease inhibitors targeting coronavirus and filovirus entry , 2015, Antiviral Research.

[44]  Limei Zhao,et al.  Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers. , 2013, International journal of clinical pharmacology and therapeutics.

[45]  Xiaoyan Chen,et al.  Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in Humans , 2013, Antimicrobial Agents and Chemotherapy.

[46]  P. Marik,et al.  Narrative Review , 2012, Journal of intensive care medicine.

[47]  D. Craik,et al.  Dermatophytic defensin with antiinfective potential , 2012, Proceedings of the National Academy of Sciences.

[48]  Ming-yuan Li,et al.  Recombinant mouse beta-defensin 2 inhibits infection by influenza A virus by blocking its entry , 2010, Archives of Virology.

[49]  Benhur Lee,et al.  Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. , 2010, The Journal of general virology.

[50]  Samson S. Y. Wong,et al.  Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus , 2008, Proceedings of the National Academy of Sciences.

[51]  J. McCullers,et al.  Chloroquine is effective against influenza A virus in vitro but not in vivo , 2007, Influenza and other respiratory viruses.

[52]  H. Xiao,et al.  Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo , 2007, Archives of Virology.

[53]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[54]  K. Subbarao,et al.  Aged BALB/c Mice as a Model for Increased Severity of Severe Acute Respiratory Syndrome in Elderly Humans , 2005, Journal of Virology.

[55]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.